GlassScriptPhysician profile
Supraja Yeturi
NPI 1528346251
$7,375.33
in general payments reported to CMS, 2019-2025
26 companies · $453 in 2025
The $453 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,995 · 2020: $634 · 2021: $1,855 · 2022: $1,834 · 2023: $157 · 2024: $448 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.58 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,858.08 | 2019-2025 | Otezla, Enbrel, Otezla |
| Abbvie INC. | $932.37 | 2019-2025 | |
| Ucb, INC. | $515.47 | 2019-2025 | Bimzelx |
| Janssen Biotech, INC. | $442.23 | 2019-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $425.33 | 2019-2022 | |
| Radius Health, INC. | $390.26 | 2019-2022 | |
| Pfizer INC. | $384.89 | 2019-2022 | |
| Glaxosmithkline, LLC. | $294.71 | 2019-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $280.17 | 2020-2022 | |
| Genentech USA, INC. | $259.85 | 2019-2024 | Actemra |
| Novartis Pharmaceuticals Corporation | $252.48 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $194.51 | 2019-2021 | |
| Celgene Corporation | $180.89 | 2019 | |
| Aurinia Pharma U.S., INC. | $171.19 | 2021-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $161.28 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $127.17 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $117.40 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.73 | 2023 | |
| Alexion Pharmaceuticals, INC. | $72.42 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $70.32 | 2019-2020 | |
| Genzyme Corporation | $44.42 | 2021 | |
| Ani Pharmaceuticals, INC. | $30.04 | 2025 | Purified Cortrophin Gel |
| Sobi, INC | $28.24 | 2025 | |
| Ardelyx, INC. | $23.79 | 2025 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $16.90 | 2021 | |
| Zyla Life Sciences, INC. | $16.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supraja Yeturi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.